Full-Time

Manager – Plasmid Process Development

Posted on 4/30/2024

Metagenomi

Metagenomi

201-500 employees

Develops gene editing tools for genetic diseases

Biotechnology

Senior

Oakland, CA, USA

Requirements
  • Undergraduate degree, advanced degree preferred in Molecular Biology or a closely related discipline
  • At least 10 (B.S.), 6 (M.S.), 3 (Ph.D.) years of industry experience in Research or Process Development
  • Experience with TFF, Akta Pure/Avant, and Chromatography systems for mRNA and plasmid
  • Nucleic acid characterization with UV absorbance, PCR, capillary/gel electrophoresis
  • Experience with LNPs and downstream activities
  • Project Management and team leadership experience
  • Extremely organized and able to efficiently manage your time and workflow, including skillfully prioritizing long-term projects and day-to-day responsibilities.
Responsibilities
  • Partner with technical operations to manufacture plasmid to support the mRNA-based gene editing systems
  • Support RNA synthesis by in-vitro transcription and nucleic acid purification
  • Support nucleic acid characterization with UV absorbance, PCR, capillary/gel electrophoresis
  • Determine Critical Process Parameters(CPPs) and partner with Metagenomi’s Analytical team to define Critical Quality Attributes (CQAs)
  • Support process optimization efforts, improving robustness and quality of mRNA and plasmid
  • Draft experimental protocols, technical reports, Batch Records, SOPs, and material specifications
  • Support technology transfers and engineering runs
  • Contribute to root cause analyses for deviations and CAPAs
  • Provide general laboratory assistance, including lab equipment maintenance, ordering of lab supplies, preparation of reagents, and compliance with safety policies

Metagenomi specializes in developing a diverse toolbox of next-generation gene editing systems, including CRISPR nucleases, base editors, prime editors, and CRISPR transposases, sourced from natural environments, with the vision to cure genetic diseases. Their proprietary sampling, high-speed screening, and sequencing, along with an AI-enabled discovery process, enable the precise and safe addressing of any target in the human genome.

Company Stage

IPO

Total Funding

$477M

Headquarters

Emeryville, California

Founded

2016

Growth & Insights
Headcount

6 month growth

0%

1 year growth

25%

2 year growth

124%